Navigation Links
Complications in patients undergoing PCI tend to occur within first 30 days
Date:3/24/2012

BOSTON, MAPercutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a balloon-tipped tube into the vessel. Sometimes a stent is also inserted to keep the blood vessel open.

While undergoing PCI treatment, doctors usually give patients medicine to prevent complications that may occur from the procedure.

In a new study by researchers at Brigham and Women's Hospital (BWH), types and timing of cardiovascular disease and heart attack (CVD/MI) complications were tracked in patients undergoing PCI after an acute coronary syndrome and taking medications to prevent these complications.

The study is being presented at the American College of Cardiology 2012 Annual Scientific Session, March 24 to 26 in Chicago.

Utilizing patients from the TRITON-TIMI 38 study, researchers examined 12,844 patients who had at least one stent and were randomized to receive either the anti-blood clotting drugs prasugrel (Effient) or clopidogrel (Plavix). These drugs work by blocking activation of platelets (a component in blood involved in clotting).

The researchers observed the patients over a median follow-up of 14.5 months.

Researchers classified CVD/MI events under three categories: stent thrombosis (when a blood clot forms in the stent), procedural-related (in the setting of PCI or bypass surgery), or spontaneous (not related to stents nor procedures, but indicating a thrombosis in a different artery than the one that caused the first acute coronary syndrome event).

There were 1,306 CVD/MI events. 186 (14 percent) were stent thrombosis-related, 606 (46 percent) were procedural-related, and 514 (40 percent) were spontaneous.

Of the 1,306 events, 846 (65 percent) occurred within the first 30 days after the PCI. Of these 846 events, the most common were procedural-related events (584, 69 percent). A total of 126 (14.9 percent) were stent thrombosis-related, and 136 (16.1 percent) were spontaneous.

For events occurring after 30 days, the majority were spontaneous (383, 81.2 percent), followed by stent thrombosis-related (63, 13.5 percent), and procedural-related (22, 4.7 percent).

CVD/MI events that occurred within the first 30 days tended to be stent thrombosis-related and procedural-related. Spontaneous CVD/MI events occurred more often in the later phase (more than 30 days after PCI).

When comparing the two drugs in the study, prasugrel reduced the incidence of CVD/MI in each event category, both early and late, with the benefit most marked among stent thrombosis-related events.

The researchers concluded that more potent anti-blood clotting drugs directly reduces complications from PCI, as well as preventing the formation of new, symptomatic thrombotic lesions in other arteries.

"These data from TRITON-TIMI 38 provide clinicians with new information regarding the timing and benefit of more potent anti-platelet agents following PCI for an acute coronary syndrome," said Benjamin Scirica, MD, MPH, BWH Cardiovascular Division, Department of Medicine, and lead study author. "It reminds us that these agents are not only preventing stent-related complications, which tend to occur early after PCI, but are also preventing the formation of new, spontaneous, thrombotic lesions throughout the coronary artery tree."


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. Drug Reduces Complications in Surgical Abortions: Study
2. Unnecessary induction of labor increases risk of cesarean section and other complications
3. Surgeons in Mid-Career Have Fewest Complications: Study
4. As Gastric Banding Increases, So May Complications
5. Patients at risk of knee joint complications when new technology is used
6. Procedure May Lower Complications After Leg Clots
7. Study finds side effects, complications, mastectomy more likely after partial breast irradiation
8. Pregnant women at low risk of complications can safely be offered a choice of where to give birth
9. Unsaturated fat breakdown leads to complications of acute pancreatitis in obese patients
10. Drugs used to tackle hospital-acquired infections can increase post-op complications
11. Some Asthma Drugs Raise Risk of Complications, Especially in Kids: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... In its efforts of bringing quality senior care ... franchise development and expansion as it welcomes Ferdie Vasquez of the new 1Heart Caregiver ... his 32 years of working in various industries. He had been a Franchise ...
(Date:4/28/2016)... ... 2016 , ... Sublime Beauty® is offering a special deal on its webstore. , Buy 1 ... is applied to the product with lesser value. In addition, a free bonus of ... more in products. , "So many women (men, too) love our products and get good ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ProText Layouts ... Final Cut Pro X . With ProText Layouts, video editors can create ... to match the length and scale of texts. Creating text-based videos have never ...
(Date:4/28/2016)... ... , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, has qualified to ... at the University of Montana on April 28-May 1. Varize will compete on Saturday ... order to qualify, Varize needed to place top seven all-around in her respective age ...
(Date:4/28/2016)... ... 2016 , ... The ARRS 2016 Annual Meeting ... from around the globe who attended a week’s worth of cutting-edge scientific presentations, ... included the introduction of the 2016 ARRS Distinguished Educator, Dr. Gerald F. Abbott, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Treato , the ... announced today that it has been named a Cool ... in Life Sciences, 2016, Stephen Davies , ... focuses on life-science- oriented analytics, algorithms and smart machine ... doctors, confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
Breaking Medicine Technology: